According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, the novel monoclonal antibody linavonkibart demonstrated the ...

Scientists discovered that certain cancer cells use a low-level activation of a DNA-dismantling enzyme—normally seen in cell death—to survive treatment. Instead of dying, these “persister cells” ...

The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of several ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common ...

Modern medicine has plenty of accidental breakthroughs, and GLP-1 drugs like Ozempic, Wegovy, and Mounjaro may be next. Trump proposes new monument near Lincoln Memorial Video of brutal Seattle attack ...

The future of cancer drug research just might be in Omaha, Nebraska, between a Panda Express and a Mattress Firm. A big draw is speed: Nordquist says he can open a trial in as little as two weeks, ...

The sexually transmitted disease has become increasingly resistant to existing antibiotics. By Andrew Jacobs The Food and Drug Administration has approved two new antibiotics for the treatment of ...

Drug-resistant gonorrhoea is on the rise worldwide, but a new antibiotic could buy us more time before the emergence of completely untreatable strains of the bacteria, which is known to potentially ...

Multiple suspects were arrested in connection with a $100 million drug trafficking bust in Southern California. Officers with the California Highway Patrol’s Inland Division have been working ...

Joe Buczek is manager of digital content and promotion at CBS Detroit. He previously worked at WWTV, the Grand Traverse Insider, the Leader and the Kalkaskian, the Oakland Press and the Morning Sun. A ...

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor growth. The technique worked even when only a fraction of tumor cells were ...

Johnson & Johnson is adding to its oncology pipeline with a $3.05 billion deal to acquire Halda Therapeutics, a startup whose first-in-class approach to prostate cancer could overcome drug resistance ...